"以前要坐车去城里的医院，现在家门口就能查，很方便！"近日，在武夷山市兴田镇汀前村，65岁的村 民王阿妹通过鹰瞳科技AI眼底相机，仅用15秒便完成了眼底扫描。3分钟后，系统生成报告提示其右眼 存在糖尿病性视网膜病变高风险。随后，她收到武夷山市立医院的转诊通知，第一时间接受治疗。这一 幕，正是武夷山市推进全民健康网格化服务、深化医防融合、借助科技赋能基层医疗的缩影。 AI赋能下沉，织密慢性病防控网 自今年3月起，武夷山市依托"健康武夷·慢病一体化管理平台"，启动2025年度65岁以上老年人及重点人 群免费健康体检工作，新增糖化血红蛋白检测和AI眼底筛查两个项目，构建起糖尿病、视网膜病变等 慢性病的"筛查-预警-干预"闭环体系。截至4月上旬，全市已为2228名糖尿病患者完成糖网、青光眼等 致盲性眼底疾病筛查，累计检出高风险病例296例，为患者争取了宝贵的救治时间窗。 "糖化血红蛋白能反映近3个月血糖控制水平，眼底血管状况则关联全身血管健康。"武夷山公立总医院 党委副书记、院长林清飞介绍，AI设备一次拍摄可同步完成糖网病变、青光眼筛查及动脉硬化风险评 估，极大提升了基层诊疗效率。 注：图文内容采编自武夷山市立医院公 ...

The Sustainability Report provides data for 2022 through 2024 on the Company’s environmental, social, and governance initiativesMENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company’s sustainability activities, performance and res ...

Aclarion (ACON) Conference Call Summary Company Overview - Aclarion focuses on addressing chronic low back pain, a significant healthcare issue in the United States and globally [1] - The company has a strong financial position with nearly $14.6 million in cash, zero debt, and is fully compliant with NASDAQ requirements [2][26] Industry Context - Chronic low back pain affects approximately 266 million people worldwide, making it the leading cost ailment in healthcare [3][4] - In the U.S., there are 635,000 spinal fusion surgeries annually, with high costs averaging $58,000 for one-level and $71,000 for two-level procedures [4] - Surgical success rates are low, with only 48-54% achieving success, and 80% of patients experiencing discomfort post-surgery [4][5] Market Opportunity - The initial addressable market for Aclarion's product, NOSI Scan, is estimated at $6.03 billion based on the fusion and disc replacement market [6] - The potential revenue increases significantly when considering other spine procedures and chiropractic care [7] Product and Technology - NOSI Scan utilizes spectroscopy to measure pain biomarkers and structural integrity within spinal discs, providing a non-invasive diagnostic alternative to traditional methods [9][12] - The technology is patented with over 40 patents worldwide, covering various aspects of the product and its application [13] Clinical Evidence and Trials - Aclarion is conducting a national randomized controlled trial called CLARITY, which is fully funded at $4.6 million, to provide robust evidence for the efficacy of NOSI Scan [3][16] - Previous studies indicate that 85% of patients improved when treated based on NOSI Scan results, compared to 63% without treatment [15][16] Regulatory and Market Strategy - The company has secured payer approvals in the UK, covering over 5.2 million people, and is working to expand its market presence [17][19] - Aclarion aims to transition its CPT codes from category three to category one to facilitate reimbursement in the U.S. [20] Management Team - The management team has extensive experience in healthcare and technology, with zero turnover since the IPO [21][24] - Key team members include a board-certified neurosurgeon and executives with backgrounds in major healthcare companies [22][24] Challenges and Future Outlook - The introduction of new technology into the payer community is challenging and requires tactical efforts to gain acceptance [34] - Aclarion is focused on building KOL advocacy and societal support to overcome reimbursement barriers [33][34] Key Takeaways - Aclarion is positioned to address a significant healthcare issue with a unique, non-invasive diagnostic tool that has strong market potential [25] - The company is well-funded and has a clear roadmap for expanding its commercial footprint and driving payer acceptance [26][27]

Financial Data and Key Metrics Changes - First quarter revenue was $2.25 billion, a 19% increase year over year, with constant currency growth at 20% [29][30] - Pro forma gross margin for Q1 was 66.4%, down from 67.6% in the same quarter last year, primarily due to higher facility costs and a mix of newer products [34] - Pro forma net income for Q1 was $662 million, or $1.81 per share, compared to $541 million, or $1.50 per share, in the prior year [37] Business Line Data and Key Metrics Changes - Da Vinci procedure growth was 17% in Q1, with significant strength in general surgery in the US and notable performance in India and Korea [9][26] - Capital placements included 367 da Vinci systems, a 17% increase from the previous year, with 147 being da Vinci V systems [10][27] - ION procedures grew 58% to approximately 31,000 in the quarter, with 49 ION systems placed [32] Market Data and Key Metrics Changes - US procedures grew 13%, driven by benign general surgery, while OUS procedures grew 24%, led by India and Korea [26][78] - Procedure growth in China improved from the prior quarter, primarily driven by urologic procedures [26] - The installed base of da Vinci systems grew 15% year over year [25] Company Strategy and Development Direction - The company aims to assure product supply globally and optimize production costs amid dynamic trade policies [7][8] - Focus on the full launch of da Vinci V and increasing adoption of focused procedures through training and market access efforts [19][20] - Commitment to building industrial scale, product quality, and manufacturing optimization [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in procedure growth, raising the full-year 2025 procedure growth forecast to 15% to 17% [39] - The impact of tariffs is expected to add approximately 1.7% to cost of sales, with a potential increase in impact as the year progresses [24][41] - Management remains cautious about the capital environment, noting potential constraints in key OUS markets due to government budget limitations [48][80] Other Important Information - The company opened new manufacturing facilities in California to expand its US manufacturing and R&D footprint [35] - The average selling price for da Vinci systems increased to $1.62 million, driven by a higher mix of da Vinci V placements [31] - The company is focused on enhancing its digital tools and computational capabilities to support surgical performance [17] Q&A Session Summary Question: Impact of tariffs on financials - Management indicated that approximately half of the tariff impact is related to US-China trade, with the remainder from imports into the US from other countries [45] Question: Capital environment and customer response - Management noted strong customer response to da Vinci V in the US, with leasing arrangements providing flexibility amid capital constraints [48] Question: OUS growth drivers - Management highlighted strong growth in early-stage markets like India and Taiwan, with ongoing efforts to engage key opinion leaders and surgical societies [80]

Core Viewpoint - The conference aimed to promote the high-quality collection, governance, secure circulation, and innovative application of healthcare data in Fujian Province, thereby empowering the high-quality development of the medical industry in the region [1][3]. Group 1: Conference Overview - The conference, themed "Digital Intelligence Integration, Medical Innovation Future," was held in Fuzhou on April 18, focusing on the value of medical data and the integration of technology and industry [1][3]. - The event featured numerous domestic and international experts discussing cutting-edge technologies, application scenarios, and policy directions in the field of medical artificial intelligence [4]. Group 2: Expert Contributions - Notable contributions included a lecture by academician Zheng Hairong from Nanjing University, who discussed the broad application prospects of artificial intelligence in healthcare, covering areas such as medical imaging, precision diagnosis, and drug screening [4]. - Other experts shared insights on health data investment funds, data construction in Fujian, and the exploration of large medical models, showcasing their research findings and practical experiences [7]. Group 3: Supply and Demand Matching - The supply and demand matching segment attracted significant attention, featuring 49 medical AI demand projects and 23 medical AI products, along with the release of the "Fujian Province Medical Artificial Intelligence Supply and Demand Matching Manual" [7][8]. - Initial cooperation intentions were established between multiple enterprises and medical institutions during the event, laying a solid foundation for future collaborations [7]. Group 4: Strategic Partnerships - A signing ceremony took place, with representatives from Fujian Province Big Data Group and other companies committing to strategic cooperation in the field of medical AI data elements [8]. - The implementation of these signed projects is expected to enhance the innovation capacity and competitiveness of Fujian's medical AI sector, injecting strong momentum into the healthcare industry [8]. Group 5: Future Development Goals - Fujian Province aims to solidify its data foundation, integrate provincial data resources, and promote innovative applications of medical data, with plans to build a smart medical system covering the entire chain of disease prevention, diagnosis, and rehabilitation [10]. - The province will also focus on attracting and cultivating high-end talent, enhancing international collaboration, and improving the overall strength and global influence of its medical AI sector [10].

Core Viewpoint - Abbott Laboratories reported better-than-expected first-quarter adjusted EPS results, showcasing strong sales growth and effective management strategies [1][2]. Financial Performance - First-quarter sales reached $10.36 billion, reflecting a year-over-year increase of 7.2%, nearly matching the consensus estimate of $10.40 billion [1]. - Adjusted EPS for the first quarter was $1.09, surpassing the consensus of $1.07 and management's guidance of $1.05-$1.09 [1]. Future Outlook - For the second quarter of 2025, Abbott Laboratories anticipates adjusted EPS in the range of $1.23-$1.27, compared to the consensus estimate of $1.25 [2]. - Following the earnings announcement, Abbott's shares increased by 0.9%, trading at $130.81 [2]. Analyst Ratings and Price Targets - Jefferies analyst Matthew Taylor maintained a Hold rating and raised the price target from $135 to $137 [7]. - Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $135 to $145 [7]. - Barclays analyst Matt Miksic maintained an Overweight rating and raised the price target from $158 to $159 [7].

WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation Oak Ridge, TN, April 17, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring'25 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 24-26, 2025. The Cardiovascular Transforum conference unites cardiovascular th ...

Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on May 8, 2025, at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that morning [1]. Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and those participating in the call can dial (833) 335-0887 using Access Code: 482081 [2]. - A replay of the call will be available on the Enovis website later that day [2]. Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [3]. - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles in orthopedics and beyond [3]. - Enovis shares are listed on the New York Stock Exchange under the symbol ENOV [3]. Group 3: Availability of Information - Enovis routinely announces material information to investors through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4]. - The company encourages investors and the media to review the information shared on its Investor Relations website [4].

Core Viewpoint - Johnson & Johnson is positioned as a resilient and growth-oriented company, capable of weathering market volatility and benefiting from its strong pipeline and consistent dividend payments [1]. Group 1: Resilience - Johnson & Johnson has a long history of resilience, having thrived through various economic challenges since its founding in 1886, generating nearly $89 billion in sales and over $14 billion in profits last year [2]. - The company's share price has increased by approximately 6% this year, contrasting with a 9% decline in the S&P 500, showcasing its ability to maintain growth despite market conditions [3]. Group 2: Growth Potential - In Q1 2025, Johnson & Johnson's sales grew by 2.4% year over year, with operational growth at 4.2%, indicating a stable growth trajectory [4]. - The company anticipates accelerated growth in the latter half of the decade, supported by six regulatory approvals for drugs this year and expectations for nine additional approvals in 2025 [4][5]. Group 3: Tariff Resistance - Johnson & Johnson is expected to be less affected by tariffs compared to other companies, with a focus on maintaining supply chain stability and investing over $55 billion in U.S. manufacturing and R&D over the next four years [6]. Group 4: Dividend Strength - The company has increased its dividend for 63 consecutive years, with a forward dividend yield of 3.37%, reinforcing its status as a Dividend King and providing investors with returns during turbulent market periods [8].

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating ...